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Introduction
Platelet activation and the formation of a multiplatelet thrombus subsequent to blood vessel injury underlie the pathophysiology of a number of cardiovascular diseases. Therapeutic intervention to prevent thrombosis involves the use of anti-coagulants or anti-platelet agents.
Anti-coagulants include direct coagulation pathway inhibitors (coumarins, heparins and thrombin catalytic site inhibitors). While clinically effective, these agents present with significant challenges and require stringent patient monitoring. Thus, much effort has been expended to develop anti-platelet agents including the widely used salicylates, GPIIb/IIIa inhibitors and ADP receptor antagonists. These agents are also clinically very useful and used widely. However there are many drawbacks and side effects that limit their use (McKee et al., 2002; Wiviott and Antman, 2004) .
Thrombin is the most potent activator of platelets, and in humans it acts on two G-protein coupled receptors, proteinase activated receptors (PARs)-1 and 4 (Coughlin, 2000) , to trigger multiple responses including platelet shape change, granule secretion and aggregation. These actions have prompted the search for drugs that target the thrombin-activated receptor, PAR1 (Andrade-Gordon et al., 1999; Bernatowicz et al., 1996; Chackalamannil et al., 2005; Serebruany et al., 2009 ). Thrombin activates PARs 1 and 4 by proteolytically unmasking an Nterminal motif that acts as a tethered ligand (TL) to initiate signaling. This TL mechanism has made development of antagonists challenging. Notwithstanding, the small molecule PAR1 peptidomimetic antagonists that have been developed (Chackalamannil et al., 2008; Chackalamannil et al., 2005; Derian et al., 2003) have resulted in clinicaly useful agents like Vorapaxar (SCH530348, trade name Zontivity) (Baker et al., 2014; Goto et al., 2010; Morrow et al., 2012a; Morrow et al., 2012b ) that block thrombin-mediated platelet aggregation whilst retaining thrombin's hemostatic clotting activity. Unfortunately, some unexpected side effects have become evident in the course of the clinical studies of Vorapaxar, including incidences of
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intracranial bleeding (Morrow et al., 2012a; Morrow et al., 2009; Pierluigi Tricoci, 2011; Tricoci et al., 2012) . While not fully understood, one explanation for the bleeding diatheses could come from the relatively widespread expression of PAR1, particularly on endothelial cells (Ramachandran, 2012) , where it has an important role in maintaining the integrity of the endothelial barrier (Bae and Rezaie, 2008; Feistritzer et al., 2006; Schuepbach et al., 2009 ).
Endothelial barrier protective responses through PAR1 are triggered by activated protein-C, as opposed to thrombin activation of PAR1, which can disrupt the endothelial barrier (Riewald and Ruf, 2005; Schuepbach et al., 2012) . More recently, compounds that target PAR1 on the intracellular face of the receptor have been developed in order to target pro-thrombotic signaling specifically through this receptor while sparing the cytoprotective signaling pathways (Aisiku et al., 2015; Dowal et al., 2011) . Thus, compounds that bind to the third intracellular loop of PAR1 inhibit Ga 13 dependent signaling (Aisiku et al., 2015) , while compounds that interact with helix 8 of PAR1 block Ga q dependent signaling (Dowal et al., 2011) .
Given the challenges in selectively blocking the detrimental effects of activating PAR1 on platelets while maintaining PAR1 cytoprotective responses in endothelial cells, we turned to the other platelet thrombin receptor -PAR4 (Xu et al., 1998) . PAR4 has a more restricted tissue expression profile and could be a more tractable therapeutic target for antiplatelet therapy in humans. Our initial studies were aimed at trying to understand the intracellular receptor motifs regulating signal transduction through PAR4. We identified an intracellular C-terminal sequence in PAR4 which regulates calcium signaling and is critical for PAR4-b-arrestin interactions. We followed on with the development of a cell penetrating peptide based on that sequence that blocks PAR4 signaling and platelet aggregation in-vitro and prevents clot consolidation in-vivo.
Molecular cloning and constructs. The plasmid encoding human PAR4 (wt-hPAR4) cloned in pCDNA3.1 (GenBank: AY431102.1) was obtained from the cDNA Resource Center (University of Michigan, Rolla, MO; currently hosted at Bloomsburg University, Bloomsburg, PA). A Cterminal eYFP (enhanced YFP) tag was fused in-frame with the PAR4 sequence by mutating the PAR4 stop codon to tyrosine and insertion of the eYFP fragment with flanking XhoI and XbaI restriction enzyme sites at the C terminus of the PAR4 coding sequence. Plasmid DNA mutations in the C-terminus of PAR4 were created using the QuikChange Lightning Multi Sitedirected Mutagenesis Kit (Agilent Technologies, Mississauga, ON) to generate all mutants described in this study. All constructs were verified by direct sequencing (University of Calgary DNA sequencing facility). Cells were transfected with FuGENE 6 (Promega) in 6-well multiplates (Nunc). Transfected cells were subcultured under G418 (600µg/ml) selection, sorted by flow cytometry, and cell stocks were maintained in liquid nitrogen for future experiments.
Calcium signaling. Calcium signaling experiments were performed essentially as described before (Mihara et al., 2013; Ramachandran et al., 2011) . Cells cultured to approximately 80% confluency in a T75 flask were detached in enzyme-free cell dissociation buffer, re-suspended in 18 ml of serum-containing growth medium, and 100 µl/well of the cell suspension was plated in black-walled cell culture-treated clear bottom 96-well plates (Corning) and cultured overnight.
The next day, adherent cells were washed with PBS and placed in 100µL of Fluo-4-AM no wash (NW) calcium indicator dye (Thermo Fisher Scientific). Intracellular fluorescence (excitation 480 nm; emission recorded at 530 nm) was monitored for 2 min after the injection of agonists (enzymes or PAR-activating peptides) into each well, using a Victor X4 plate reader (PerkinElmer Life Sciences). The increase in fluorescence emission monitored at 530 nm was used as an index of increases in intracellular calcium. In some experiments calcium signaling was also monitored in Fluo4 loaded cells in suspension on an AB2 spectrofluormeter (Thermo Life Science). Where appropriate, responses were normalized to the calcium signal generated This article has not been copyedited and formatted. The final version may differ from this version. by 2 µM of A23178 (Sigma), a calcium ionophore.
MAPKinase assay. Agonist-stimulated MAPKinase signaling in HEK-293 cells expressing wt-PAR4-YFP or dRS-PAR4-YFP was monitored by western blot analysis as described previously (Mihara et al., 2013; Ramachandran et al., 2011) . In brief, cells were rinsed with PBS and placed in serum free media. Cells were then stimulated with agonists for varying time periods, rapidly rinsed with ice-cold isotonic phosphate-buffered saline and placed on ice. Total protein was extracted by adding ice-cold lysis buffer (20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 10 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 0.5 % NP40, 2.5 mM sodium pyrophosphate, 1 mM betaglycerophosphate, 1 mM Na 3 VO 4 , 25 mM NaF, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 1 mM PMSF and 1mM DTT) and cleared by centrifugation (15,000Xg for 10 minutes). The protein samples were heat-denatured at 92°C for 10 min in denaturing Laemmli buffer and resolved on using the same protein extraction and western blotting procedures described above. Cell were stimulated with agonists for 10 minutes and all antagonist pre-treatments was done for 20 minutes.
Confocal microscopy. HEK-293 cells transfected with wt-PAR4-YFP or dRS-PAR4-YFP with FuGENE 6 in six well plates were sub-cultured into 35 mm glass bottom culture dishes (MatTek) and placed in growth medium for an additional 16 hours. Cells were stimulated with agonists for specified times, fixed with 10% buffered formalin and receptor trafficking was monitored by imaging eYFP expression with an Olympus FV1000 confocal microscope system on an Olympus IX70 microscope using the fluoview system software.
BRET detection of b-arrestin recruitment. Resonance Energy Transfer-based detection of b-
Arrestin-1 and -2 interaction with wt-PAR4-YFP and dRS-PAR4-YFP was monitored in HEK-293 cells as described (Ramachandran et al., 2011; Ramachandran et al., 2009) Solution. Platelet aggregation studies were done in washed platelets. The blood was centrifuged at 300g for 15 min and the platelet rich plasma was transferred to 50 ml conical tubes containing 10% acid citrate dextrose (ACD) solution (39mM citric acid, 75mM sodium citrate, 135mM
glucose, pH 7.4). Following another centrifugation step at 800g the pelleted cells were resuspended in tyrode's buffer (12mM NaHC0 3 , 127mM NaCl, 5mM KCl, 0.5mM NaH 2 PO 4 , 1mM MgCl2, 5mM glucose and 10mM HEPES), counted on a coulter counter, and adjusted to a concentration of 3X10 8 cells/ml. 400µL of this cell suspension was used for light transmission aggregometry on a platelet aggregometer (Chrono-Log Corp, Havertown, PA).
Confocal intravital imaging in-vivo.
Mice (8-10 week old male C57BL/6) were injected intraperitoneally with 20 mg/kg RAG8 or the control reverse-RAG8 in 100µl of isotonic phosphate-buffered saline pH 7.4. Mice were then anesthetized (10 mg per kg body weight xylazine hydrochloride and 200 mg per kg body weight ketamine hydrochloride), and body temperature was maintained using a heating pad. The right jugular vein was cannulated to administer additional anesthetic and fluorescent labels. Platelets were labeled with a CD49b antibody coupled to Alexa 647 (Biolegend, 5µg/mouse) and blood vessels were labeled with an anti-CD31 (PECAM) antibody coupled to PE (ebioscience, 2µg/mouse). The femoral artery and vein were surgically exposed, baseline readings were taken and a 1-2 mm 2 filter paper soaked in 10% FeCl3 was placed on the blood vessels for 3 min. The injury site was rinsed thoroughly
This article has not been copyedited and formatted. The final version may differ from this version. and 730 nm (Cobalt) was used in rapid succession, and fluorescence in green, red and blue channels was visualized with the appropriate long-pass filters (Semrock). Exposure time for all wavelengths was constant at 1s. Sensitivity settings were kept the same for all experiments. A 512 X 512 pixel back-thinned EMCCD camera (C9100-13, Hamamatsu) was used for fluorescence detection. Volocity Acquisition software (Improvision) was used to drive the confocal microscope. Images captured using the spinning disk were processed and analyzed in Volocity 4.20. Thrombus area was quantified over the entire field of view for each treatment using the Volocity software.
Measurement of tail vein bleeding times (TVBTs).
Mice were injected with 20mg/kg RAG8 or control reverse-RAG8 and anesthetized with an i.p. injection of Ketamine/Xylazine (10 mg per kg body weight xylazine hydrochloride and 200 mg per kg body weight ketamine hydrochloride).
The tails were transected 0.5 cm from the tip and placed in a cuvette containing saline at 37˚C.
The time taken for the cessation of blood flow was monitored. Once blood flow had stopped, the vein was monitored for a further 60 seconds to confirm stable occlusion. If blood flow resumed within the one-minute time-frame, the time taken for cessation of continued blood flow was monitored again up to 800 seconds.
Statistical Analysis. Statistical analysis of data and curve fitting were done with Prism 5 software (GraphPad Software, San Diego, CA). Statistical significance was assessed using the Student's t-test or Anova with Tukey's post-test.
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Results
Impaired calcium signaling via C-terminal mutant PAR4 receptors. Based on sequence alignment, we initially observed that human PAR4 lacked a cysteine residue that is present in the rodent PAR4 (C368 in mouse PAR4) C-terminus, in the human PAR1 (C387-388) and in PAR2 (C361). Since C-terminal cysteine residues serve as sites of receptor palmitoylation and regulate signaling (Qanbar and Bouvier, 2003) , we generated mutant PAR4 receptors QC-PAR4
where the glutamine is mutated to a cysteine, as well as a variant which had an 8 amino acid deletion flanking this region (dRS-PAR4) ( Table 1 ).
In figure 3C) . Thus we conclude that the C-terminal 8-amino acid PAR4 motif that we have identified regulates calcium signaling, b-arrestin interaction with PAR4 and the internalization of activated receptors.
Targeting signaling involving the PAR4 C-terminal RAG8 domain with cell penetrating
peptides. Having identified a key regulatory sequence in the PAR4 C-terminus, we investigated if we could pharmacologically target this motif to modify receptor function using a cellpenetrating palmitoylated peptide (a pepducin) in keeping with the approach developed for other GPCRs (Tressel et al., 2010) . Therefore, to target the C-terminus of PAR4 we synthesized a peptide with a sequence corresponding to the identified 8-amino acid motif in PAR4
(RAGLFQRS), coupled to an N-terminal palmitoyl moiety (RAG8) and C-terminal NH 2 ( Figure   3A ). A control peptide had an identical architecture but with the reverse amino acid sequence (SRQFLGAR: SRQ8). We then investigated the ability of these peptides to regulate PAR4 function in various assays. At 10µM, RAG8 attenuated calcium signaling triggered by 10, 30 and 100µM of the PAR4 agonist peptide AYPGKF-NH2 ( Figure 3B ). Similarly, both b-arrestin-1 and b-arrestin-2 recruitment to AYPGKF-NH2 activated PAR4 were significantly attenuated by 10µM RAG8 ( Figure 3C and D). RAG8 had no effect on the related GPCR, Proteinase Activated
Receptor-2 recruitment of b-arrestin1 and 2 (Supplementary Figure 4) .
Targeting PAR4 to regulate platelet function. Previous work has shown that b-arrestin-2
supports PAR4 signaling in murine platelets, enabling platelet fibrinogen binding and thrombus formation . We therefore hypothesized that by interdicting the PAR4-arrestin interaction with our RAG8 pepducin, we would affect PAR4-mediated platelet aggregation and clot consolidation. Indeed, in assays done with washed human platelets, RAG8 inhibited platelet aggregation stimulated by the PAR4 agonist peptide (AYPGKF-NH 2 ), but not by the PAR1
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Since AKT signaling is known to be involved in murine platelet activation (Woulfe et al., 2004) , we investigated whether PAR4 activation could trigger AKT phosphorylation in human platelets and whether RAG8 modulates this process ( Figure 4C ). In washed human platelets, the PAR4 agonist peptide and thrombin triggered an increase in phospho-AKT. RAG8 alone did not trigger a significant elevation of p-AKT, while RAG8 inhibited the AYPGKF-NH 2 and thrombin triggered elevation of AKT activation in a concentration-dependent manner ( Figure 4C and D) .
Targeting PAR4 to regulate thrombus formation in-vivo. Because we were able to block platelet aggregation with our RAG8 pepducin in-vitro, we next tested its ability to affect thrombosis in-vivo in a rodent model where platelet function is regulated by PAR4 in the absence of PAR1. We used spinning disc confocal microscopy to monitor murine thrombus formation following FeCl 3 blood vessel injury of blood in the presence and absence of either RAG8 or the control peptide, SRQ8. In keeping with our results in-vitro with washed platelets, we observed a significant inhibition of thrombosis at 15-30 minutes after FeCl 3 injury ( Figure 5A and B) in RAG8-treated mice but not in SRQ8-treated animals. Upon analysis of the video recording of thrombus formation in real time after treatment with RAG8, we observed that at early time points following FeCl 3 injury, the platelet thrombus does develop, but then very rapidly disintegrates and is washed away. This result suggested that RAG8 interferes with stabilization and consolidation of the platelet thrombus (Supplementary Video 1). This conclusion was supported by our observations using a tail-bleeding assay. We observed that in control mice, bleeding from the tail vein ceased completely at the 3-minute time point. However, in RAG8 treated mice, whilst bleeding also ceased at the 3-minute mark, blood flow then resumed, in some instances up to the 15-minute time point when the experiment was concluded ( Figure 5C ).
This result indicated that the thrombus failed to stabilize.
Discussion
Our main finding was that a specific motif in the C-terminus of PAR4 (RAGLFQRS) coordinately regulated calcium signaling and interactions of the receptor with b-arrestins 1 and 2. Yet, the receptor missing this domain was nonetheless able to trigger activation of MAPKinase. Further, by targeting this sequence with a cell-penetrating peptide (RAG-8), we were able to block PAR4-dependent platelet activation in-vitro and to attenuate clot stabilization in-vivo without affecting signaling by PAR1. The impact of the RAG-8 peptide on platelet aggregation and clot consolidation can be linked to its inhibition of Akt activation, which has been identified as a key arrestin-dependent signaling event for platelet activation Woulfe et al., 2004) .
Our work thus underscores the utility of targeting PAR4 as an antithrombotic strategy, as an alternative to blocking platelet activation by PAR1. Our finding that deletion of a C-terminal motif disrupts Ga q dependent calcium signaling in addition to b-arrestin recruitment was unexpected since mutational and structural studies have shown that G-protein-receptor interactions occur through contacts at the intracellular loops and transmembrane helices (TM) of GPCRs Rasmussen et al., 2011; Venkatakrishnan et al., 2013) . While further work is required to understand the exact mechanisms, it is possible that the loss of signaling could come from a disruption of the network of receptor ionic and hydrogen-bond interactions, that may form a so called 'ionic lock' in the PAR4 carboxyl tail (Audet and Bouvier, 2012) .
It is also interesting that dRS-PAR4 activation could still trigger MAPK signaling, suggesting that this occurs in a b-arrestin and Ga q independent manner, likely through Ga 12/13 activation (Voss et al., 2007) . In human platelets PAR4 does not interact with Ga i (Voss et al., 2007) , however PAR4 coupling to Ga i is reported in endothelial cells (Hirano et al., 2007) . Using the P4pal10 pepducin that targets the intracellular loop 3 (ICL3) of PAR4 we were able to attenuate p38 MAPK signaling, pointing to ICL3 as the Ga 12/13 or Ga i interacting domain. Thus, our data Our approach to blocking PAR4 activation complements the development of presumed orthosteric inhibitors of the receptor that are thought to target the tethered ligand docking site, like YD-3 (Wu et al., 2000; Wu et al., 2002) and substituted indoles based on the YD-3 structure such as ML354 (Wen et al., 2014; Young et al., 2013 ). The precise mechanism of antagonism of the indole-related compounds has not yet been determined. Further, whether the RAG-8 sequence we have identified interacts directly with effectors like Ga q and the arrestins to modulate signaling or rather regulates the conformation of the C-terminal domain so as to change those interactions remains to be determined. Since we could not detect any inhibition of PAR1 or PAR2 signaling, RAG8 does appear to be a PAR4 specific inhibitor. The exact mechanism of action however remains to be elucidated. Nonetheless, the mechanisms whereby the indole-related compounds and the RAG-8 pepducin block PAR4 activation will undoubtedly differ. Since PAR4 subserves many physiological functions apart from regulating platelet reactivity, it will very likely be of value to block its actions in a pathway selective manner, as per the RAG-8 antagonist, rather than blocking all of its actions.
The mechanisms by which PAR4 stabilizes the platelet thrombus are not yet fully worked out, but PAR4 acts upstream of other factors that act to stabilize the platelet thrombus including the activation of the P2Y12 receptors (Cornelissen et al., 2011; Holinstat et al., 2006; Kim et al., 2002; Li et al., 2011) and may serve as an important node for multiple thrombin dependent responses in platelets. Thus, inhibition of PAR4 could prevent the formation of large occlusive thrombi, without preventing the formation of the small juxtamural thrombus that develops as a result of thrombin activation of PAR1. This selective inhibition of PAR4 that enables perivascular homeostasis may be of particular relevance in individuals with a PAR4 mutation that renders their platelets more susceptible to PAR4 activation (Edelstein et al., 2014; Edelstein et al., 2013 ).
In conclusion, we have uncovered a novel molecular determinant of PAR4 signaling involving its C-terminal domain and have developed a cell-penetrating peptide based on this sequence that blocks PAR4-stimulated platelet activation and thrombus consolidation. This inhibition of PAR4
provides an attractive alternative to blocking PAR1 for dealing with vascular occlusive disease.
We believe that this signaling mechanism may also be a therapeutic target in other settings where PAR4 can be involved and propose that the use of RAG8 could also be of benefit in pathologies such as pain and inflammatory disease (Mao et al., 2010; McDougall et al., 2009) where PAR4 is thought to play an important role.
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WT-PAR4-YFP SAEFRDKVRAGLFQRSPGDTVASKASAE-YFP
QC-PAR4-YFP SAEFRDKVRAGLFCRSPGDTVASKASAE-YFP
dRS-PAR4-YFP SAEFRDKV--------PGDTVASKASAE-YFP
